circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X Cytokinetics Analyst & Investor Day: Charting the Commercial Course
    Oct 7, 2021 8:30 AM EDT

    Cytokinetics Analyst & Investor Day: Charting the Commercial Course
    Oct 7, 2021 8:30 AM EDT
  • Webcast
    X Cantor Virtual Global Healthcare Conference
    Sep 27, 2021 3:20 PM EDT

    Cantor Virtual Global Healthcare Conference
    Sep 27, 2021 3:20 PM EDT
  • Webcast
    X Morgan Stanley 19th Annual Global Healthcare Conference
    Sep 14, 2021 11:45 AM EDT

    Morgan Stanley 19th Annual Global Healthcare Conference
    Sep 14, 2021 11:45 AM EDT
  • Webcast
    X H.C. Wainwright 23rd Annual Global Investment Conference
    Sep 13, 2021 12:00 PM EDT

    H.C. Wainwright 23rd Annual Global Investment Conference
    Sep 13, 2021 12:00 PM EDT
  • Webcast
    X HFSA Investor Call/Webcast
    Sep 13, 2021 8:30 AM EDT

    HFSA Investor Call/Webcast
    Sep 13, 2021 8:30 AM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics to Host Analyst & Investor Day on October 7, 2021
SOUTH SAN FRANCISCO, Calif. , Sept. 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host an Analyst and Investor Day on Thursday, October 7, 2021 from 8:30 AM to 11:30 AM ET . The event will be held at the Westin Grand Central Hotel in New York
Toggle Summary Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
Full Results from REDWOOD-HCM Demonstrate Improvements in Biomarkers and Heart Failure Symptoms in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten  Supporting Progression to Phase 3 Clinical Trial Additional Results from GALACTIC-HF Show Effect of Treatment with
Toggle Summary Cytokinetics to Participate in September Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to participate in the following investor conferences in September: H.C.
Toggle Summary Cytokinetics to Host Investor Call and Webcast to Discuss the Full Results From Redwood-HCM at the HFSA Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host a conference call and webcast on September 13, 2021 at 8:30 AM Eastern Time to discuss the full results from REDWOOD-HCM ( R andomized E valuation of D osing W ith